Drug Approval | January 30, 2023
FDA approves Keytruda as adjuvant treatment for non-small cell lung cancer
Approval marks fifth indication for KEYTRUDA-based regimens in NSCLC and 34th indication for KEYTRUDA in the US
Approval marks fifth indication for KEYTRUDA-based regimens in NSCLC and 34th indication for KEYTRUDA in the US
It will help upgrade the infrastructure and technologies of the country's biopharmaceuticals and in-vitro diagnostic industry
OmiCrisp has been developed with support from Centre for Cellular And Molecular Platforms C-CAMP-InDx Program
The company is adding new capabilities of Combi-line for Microsphere, additional Bag line and lyos for the Penem block in Pashamylaram facility in Hyderabad and will be earmarking capital for further building on its Biosimilar CDMO facility
He was previously associated with renowned companies such as Granules India Ltd, Dr. Reddy’s Laboratories ltd & Aptar Group
The goal is to bring oncology therapy closer to the communities by integrating all services such as chemotherapy and radiation centers
Sacu V is priced at Rs. 19 per tablet for a dose of 50 mg (sacubitril 24 mg + valsartan 26 mg)
India's G20 Presidency will focus on three main priorities: Health Emergencies Prevention, Preparedness and Response (One Health & AMR); Access and Availability to Affordable Medical Countermeasures (Vaccines, Therapeutics, and Diagnostics); and Digital Health
The company remains committed to maintain the highest standards of compliance and will work closely with the agency to comprehensively address all the observations
Subscribe To Our Newsletter & Stay Updated
